Orient EuroPharma Co., Ltd. (TPEX:4120)
Taiwan
· Delayed Price · Currency is TWD 46.50
+0.20 (0.43%)
Apr 29, 2026, 11:31 AM CST
Orient EuroPharma Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 4,595 | 4,391 | 4,592 | 4,730 | 4,767 | Upgrade
|
| Revenue Growth (YoY) | 4.64% | -4.37% | -2.93% | -0.77% | -11.45% | Upgrade
|
| Cost of Revenue | 2,358 | 2,325 | 2,445 | 2,698 | 2,616 | Upgrade
|
| Gross Profit | 2,237 | 2,066 | 2,147 | 2,032 | 2,151 | Upgrade
|
| Selling, General & Admin | 1,978 | 1,811 | 1,868 | 1,922 | 1,918 | Upgrade
|
| Research & Development | 558.41 | 242.22 | 206.6 | 259.84 | 331.09 | Upgrade
|
| Operating Expenses | 2,548 | 2,073 | 2,077 | 2,182 | 2,246 | Upgrade
|
| Operating Income | -310.54 | -6.72 | 70.61 | -149.54 | -95.68 | Upgrade
|
| Interest Expense | -74.06 | -107.23 | -106.1 | -69.53 | -38.04 | Upgrade
|
| Interest & Investment Income | 34.38 | 48.87 | 50.86 | 20.96 | 11.85 | Upgrade
|
| Earnings From Equity Investments | -61.01 | -27.29 | -18.27 | -30.14 | -19.14 | Upgrade
|
| Currency Exchange Gain (Loss) | 88.13 | -111.86 | -25.59 | -177.51 | 11.6 | Upgrade
|
| Other Non Operating Income (Expenses) | 57.04 | 71.11 | 50.08 | 40.54 | 41.69 | Upgrade
|
| EBT Excluding Unusual Items | -266.07 | -133.1 | 21.6 | -365.23 | -87.71 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 6.15 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 1.41 | -4.83 | 234.5 | 72.35 | 182.38 | Upgrade
|
| Asset Writedown | -8.65 | - | - | -35.3 | -10 | Upgrade
|
| Other Unusual Items | 0.28 | 1.8 | 0.16 | 0.05 | 0.1 | Upgrade
|
| Pretax Income | -273.03 | -129.99 | 256.25 | -328.14 | 84.77 | Upgrade
|
| Income Tax Expense | 207.16 | 101.21 | 86.97 | -32.77 | 10.47 | Upgrade
|
| Earnings From Continuing Operations | -480.19 | -231.2 | 169.29 | -295.37 | 74.3 | Upgrade
|
| Minority Interest in Earnings | -87.2 | -52.74 | -25.34 | -15.44 | 45.88 | Upgrade
|
| Net Income | -567.39 | -283.93 | 143.94 | -310.8 | 120.17 | Upgrade
|
| Net Income to Common | -567.39 | -283.93 | 143.94 | -310.8 | 120.17 | Upgrade
|
| Net Income Growth | - | - | - | - | -39.70% | Upgrade
|
| Shares Outstanding (Basic) | 87 | 87 | 87 | 87 | 87 | Upgrade
|
| Shares Outstanding (Diluted) | 87 | 87 | 87 | 87 | 87 | Upgrade
|
| Shares Change (YoY) | - | -0.23% | 0.23% | -0.24% | -0.21% | Upgrade
|
| EPS (Basic) | -6.54 | -3.27 | 1.66 | -3.58 | 1.39 | Upgrade
|
| EPS (Diluted) | -6.54 | -3.27 | 1.66 | -3.58 | 1.38 | Upgrade
|
| EPS Growth | - | - | - | - | -39.74% | Upgrade
|
| Free Cash Flow | -465.88 | -220.16 | -34.73 | -857.91 | -1,485 | Upgrade
|
| Free Cash Flow Per Share | -5.37 | -2.54 | -0.40 | -9.89 | -17.08 | Upgrade
|
| Dividend Per Share | 4.000 | 1.000 | 1.000 | - | 0.850 | Upgrade
|
| Dividend Growth | 300.00% | - | - | - | -43.33% | Upgrade
|
| Gross Margin | 48.69% | 47.05% | 46.76% | 42.96% | 45.12% | Upgrade
|
| Operating Margin | -6.76% | -0.15% | 1.54% | -3.16% | -2.01% | Upgrade
|
| Profit Margin | -12.35% | -6.47% | 3.14% | -6.57% | 2.52% | Upgrade
|
| Free Cash Flow Margin | -10.14% | -5.01% | -0.76% | -18.14% | -31.16% | Upgrade
|
| EBITDA | -155.08 | 153.46 | 235.75 | 7.04 | 60.33 | Upgrade
|
| EBITDA Margin | -3.38% | 3.50% | 5.13% | 0.15% | 1.27% | Upgrade
|
| D&A For EBITDA | 155.46 | 160.18 | 165.14 | 156.57 | 156.01 | Upgrade
|
| EBIT | -310.54 | -6.72 | 70.61 | -149.54 | -95.68 | Upgrade
|
| EBIT Margin | -6.76% | -0.15% | 1.54% | -3.16% | -2.01% | Upgrade
|
| Effective Tax Rate | - | - | 33.94% | - | 12.35% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.